Sector News

Baxter’s CDMO arm will add 100 new positions in $50M fill-finish expansion of Indiana plant

November 27, 2020
Life sciences

In recent months, the contract manufacturing market has seen a wave of investment in the U.S. amid the COVID-19 pandemic and a call for “onshore” drug production. Now, Baxter’s CDMO arm is stepping up to the plate with a finishing technology expansion at its Indiana site.

Baxter Biopharma Solutions, the CDMO arm of healthcare giant Baxter, will shell out $50 million in an expansion to its fill-finish manufacturing plant in Bloomington, Indiana, that will eventually bring 100 new positions on board, the company said Tuesday.

The expansion will add a 25,000-square-foot warehouse; a new filling line for flexible plastic containers; a high-speed automated syringe fill line capable of filling up to 600 units per minute; and a new high-speed, automated visual inspection line, Baxter said.

Construction has already begun and is expected to be completed in 2021, Baxter said. The CDMO will then begin taking on contracts in 2022.

The Bloomington site handles clinical and commercial manufacturing for drugs from roughly 25 biopharma companies, Baxter said in a release.

Baxter and its CDMO arm have had a relatively quiet past few years for a multibillion-dollar global enterprise.

Back in 2016, the firm agreed to buy sterile injectables specialist Claris Lifesciences for $625 million, which added three manufacturing facilities, 11 drugs approved in the U.S. and a pipeline of other products. Baxter said the addition of the Indian drugmaker would allow the combined company to launch seven to nine new products a year in the short term and up to 15 products a year after 2019.

In early 2017, the company settled federal claims that it distributed “adulterated” sterile injectables products from a legacy manufacturing site plagued by mold and paid $16 million in penalties and forfeiture as part of a deferred prosecution agreement. It also agreed to regularly report on improvements made to its manufacturing operations.

by Kyle Blankenship

Source: fiercepharma.com

comments closed

Related News

May 10, 2025

FDA approves Teal Health HPV screening test as an at-home alternative to the Pap smear

Life sciences

According to a study conducted by the company that included more than 600 participants, samples collected with the Teal Wand were shown to be just as accurate as those taken by a clinician during an office visit. About 94% of participants said they would opt for self-collection in the future, and 86% said they felt they would be more likely to stay up to date with cervical cancer screening if they could do it at home.

May 10, 2025

FDA appoints first chief AI officer as it looks to speed up reviews

Life sciences

Jeremy Walsh was named head of IT and AI, according to his post on LinkedIn. The move was first reported by Politico. Walsh previously held the role of chief technologist at Booz Allen Hamilton, managing AI- and cloud-based projects for 14 years at the consultancy.

May 10, 2025

Roquette announces a new organization following the acquisition of IFF Pharma Solutions

Life sciences

The new organization features two Business Groups that will rely on dedicated teams and assets to fully focus on meeting customer and market needs. Isabelle Bouvier is appointed as CEO of the Health & Pharma Solutions Business Group and Pascal Leroy as CEO of the Nutrition & Bioindustry Business Group. Béatrice Totel replaces Isabelle Bouvier as CFO of Roquette.

How can we help you?

We're easy to reach